Trial document




This trial has been registered retrospectively.
drksid header

  DRKS00014760

Trial Description

start of 1:1-Block title

Title

Analysis of glioblastoma-metabolism by MRI-Spectroscopy

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

In a joint research project of the clinic of neurosurgery and the clinic of neuroradiology Kiel we aim to examine the metabolism of intracerebral Tumors with MR-spectroscopy. This research focused on getting further information about the so called Warburg-effect. This effect describes the suspicion that tumor cells gain energy through an oxygen-independent metabolism despite the availability of oxygen. This mechanism could enable the tumor cells to cover the demand of the high energy requirement caused by fast tumor growth.
By a special MR-examination, the MR-spectroscopy, it is possible to measure the morphological distribution of metabolites and quantify them. We are especially interested in the distribution of lactate, which is one if the produced metabolites concerning the Warburg-effect.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The Glioblastoma multiforme is the most common and most malign primary brain tumor. Currently there are still no curative therapy-regimes available. Responsible for this poor prognosis are b.o. the fast growth of the tumor although there are no energy substrates available and the early migration of the tumor cells. To enable this aggressive attributes the tumor cells are able to undergo molecular changes, which f.e. lead to a change of the metabolism.
Already in the 20th century a German scientist and later Nobelist Otto Warburg hypothesized that the raised lactate-levels of Tumor cells are caused by an oxygen independent glycolysis of the cells. This process, since then named Warburg effect and hallmark of severe tumorentities, seems to be an adjustment mechanism enabling the tumor cells to cover the high energy demand caused by fast tumor growth.
Meanwhile a diagnostic procedure found its way into daily work which can provide important information about the metabolism of intracranial Tumors without being invasive or using ionizing radiation. The hereby described MR-sprectroscopy just takes a few minutes and is already used to further distinguish between primary brain tumors and metastasis. Lactate is one of the hereby measured metabolites. Molecular-biological examinations let us suggest that lactate is mostly exported in the hypoxic center of the Glioblastoma and gets again absorbed in the vesiculated tumor parts for producing energy. In this field further detailed studies using MR-spectroscopy are currently not available.
In this setting we plan to exploit preoperative MR-spectroscopies of brain tumors.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

No

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00014760
  •   2019/03/05
  •   [---]*
  •   yes
  •   Approved
  •   D 444/18, Ethikkommission der Christian-Albrechts-Universität zu Kiel
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C71.9 -  Malignant neoplasm: Brain, unspecified
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   In the study, an MRI spectroscopy (a measurement lasting only a few minutes) is carried out in order to be able to detect any differences in tumor metabolism in the tumor center and peripheral area. All patients are examined who are suspected of having a brain-specific tumor and who have given their consent after detailed information. A total of at least 10 patients should be examined.
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Other
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Basic research/physiological study
  •   Single (group)
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Minimum 10 patients should be examinated with MRS (magnetic resonance spectroscopy). The results of edge and central regions of the tumor will be compared.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

The data-research is to be continued for about three years.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2018/05/14
  •   20
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Intracranial tumors

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

in need of protection (children)

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Abt. Neurochirurgie UKSH Kiel
    • Mr.  Prof.  Michael  Synowitz 
    • Arnold-Heller-Str. 3
    • 24105  Kiel
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Klinik für Neurochirurgie am UKSH, Campus Kiel
    • Ms.  Dr. med.  Carolin  Kubelt 
    • Arnold-Heller-Straße 3
    • 24105  Kiel
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Klinik für Neurochirurgie am UKSH, Campus Kiel
    • Ms.  Dr. med.  Carolin  Kubelt 
    • Arnold-Heller-Straße 3
    • 24105  Kiel
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Klinik für Neurochirurgie am UKSH, Campus Kiel
    • Mr.  Prof.  Michael  Synowitz 
    • Arnold-Heller-Straße 3
    • 24105  Kiel
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2020/04/15
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.